Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After Earnings Growth And New XINYUE Indication Approval

Simply Wall St.04-04

AdvertisementWhat the latest earnings and drug news mean for Hansoh Pharmaceutical Group The latest move in Hansoh Pharmaceutical Group (SEHK:3692) is being shaped by two fresh developments: full year...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2624618973?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-04-04 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624618973","market":"hk","top_or_hot":-1,"title":"Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After Earnings Growth And New XINYUE Indication Approval","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat the latest earnings and drug news mean for Hansoh Pharmaceutical Group The latest move in Hansoh Pharmaceutical Group (SEHK:3692) is being shaped by two fresh developments: full year...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft-1\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After Earnings Growth And New XINYUE Indication Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After Earnings Growth And New XINYUE Indication Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-04 20:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft-1><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat the latest earnings and drug news mean for Hansoh Pharmaceutical Group The latest move in Hansoh Pharmaceutical Group (SEHK:3692) is being shaped by two fresh developments: full year...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft-1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1589","symbol_name":"北水核心资产","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft-1","article_id":"2624618973","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/assessing-hansoh-pharmaceutical-group-sehk3692-valuation-aft-1","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2624618973","pubTimestamp":1775305316,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What the latest earnings and drug news mean for Hansoh Pharmaceutical Group\nThe latest move in Hansoh Pharmaceutical Group (SEHK:3692) is being shaped by two fresh developments: full year 2025 earnings and new regulatory progress for its autoimmune drug XINYUE in China.\nFor the year ended 31 December 2025, Hansoh Pharmaceutical Group reported sales of CN¥15,028.32 million, compared with CN¥12,260.81 million a year earlier, and net income of CN¥5,555.46 million versus CN¥4,371.83...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1589":"北水核心资产","BK1191":"制药","BK1583":"高瓴概念","03692":"翰森制药","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"评估翰森制药集团（SEHK：3692）盈利增长和新欣悦适应症获批后的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9,"DCF":1},"content_text":"AdvertisementWhat the latest earnings and drug news mean for Hansoh Pharmaceutical Group The latest move in Hansoh Pharmaceutical Group (SEHK:3692) is being shaped by two fresh developments: full year 2025 earnings and new regulatory progress for its autoimmune drug XINYUE in China. For the year ended 31 December 2025, Hansoh Pharmaceutical Group reported sales of CN¥15,028.32 million, compared with CN¥12,260.81 million a year earlier, and net income of CN¥5,555.46 million versus CN¥4,371.83 million. Basic earnings per share from continuing operations came in at CN¥0.93, compared with CN¥0.74 a year earlier, while diluted earnings per share from continuing operations were CN¥0.93, compared with CN¥0.73 a year earlier. Alongside these results, investors are also weighing new product news. On 25 March 2026, XINYUE (Inebilizumab Injection) received China National Medical Products Administration approval for an additional indication in generalized myasthenia gravis in certain adult patients. This new use is the third approved indication for XINYUE, which is a targeted CD19 B cell depleting antibody. The product is now cleared in China when used with conventional therapies to treat adult generalized myasthenia gravis patients who are positive for anti acetylcholine receptor or anti muscle specific tyrosine kinase antibodies. Hansoh Pharmaceutical Group holds exclusive rights to develop and commercialize XINYUE across Mainland China, Hong Kong and Macau under a licence agreement originally signed with Viela Bio, which later became part of Horizon Therapeutics and then Amgen. See our latest analysis for Hansoh Pharmaceutical Group. The latest share price of HK$39.36 comes after a 1 day share price return of 5.18% and a 7 day share price return of 20.88%. The 1 year total shareholder return of 67.93% and 3 year total shareholder return of 188.18% point to strong longer term momentum around the business and its pipeline updates. If earnings news and drug approvals have you thinking about what else might be moving, this is a good moment to look beyond a single stock and scan 125 healthcare AI stocks With earnings climbing, a growing pipeline and the share price already up 67.93% over 1 year, the key question is whether Hansoh at HK$39.36 still trades at a discount or if the market is already pricing in future growth. Price-to-earnings of 37.7x: Is it justified? Hansoh currently trades on a P/E of 37.7x, a level that sits well above both its own estimated fair P/E and the wider Hong Kong pharmaceuticals group. The P/E multiple compares the share price to earnings per share. A higher figure generally means investors are paying more today for each unit of current earnings. For a drug maker with established products and active R&D, a richer P/E often suggests the market is focusing on future profit potential rather than just the most recent numbers. In Hansoh's case, the current P/E of 37.7x is described as expensive versus the estimated fair P/E of 29x. This is the level the SWS fair ratio suggests the market could move toward based on underlying fundamentals. That gap implies investors are currently accepting a higher price for each dollar of earnings than the model indicates, even though earnings growth is forecast at 10.6% per year and is described as growing but not significantly. Compared with peers, the contrast is even starker. The stock's 37.7x P/E stands above the peer average of 24.8x and also above the broader Hong Kong pharmaceuticals industry average of 15.4x. This points to a premium valuation relative to both direct competitors and the sector overall. Explore the SWS fair ratio for Hansoh Pharmaceutical Group Result: Price-to-earnings of 37.7x (OVERVALUED) However, you also have to keep an eye on regulatory setbacks around key drugs and any loss of momentum in China-only revenue, both of which could hit sentiment. Find out about the key risks to this Hansoh Pharmaceutical Group narrative. Another view from the SWS DCF model The P/E points to an expensive share price, but the SWS DCF model tells a different story. On that measure, Hansoh at HK$39.36 is trading about 15% below an estimated future cash flow value of HK$46.44. This frames today’s price as a potential discount. So which signal do you trust most? Look into how the SWS DCF model arrives at its fair value. 3692 Discounted Cash Flow as at Apr 2026Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hansoh Pharmaceutical Group for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 247 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity. Next Steps If the mixed signals on valuation and sentiment leave you unsure, this is the moment to look at the underlying data yourself and move quickly. To see what investors are optimistic about, take a closer look at the 3 key rewards Ready to hunt for your next idea? If Hansoh has sharpened your focus, do not stop here. The best opportunities often sit just outside your current watchlist, so broaden your search now.  Target high quality companies that combine strong fundamentals with room for a re rating by scanning 247 high quality undervalued stocks. Strengthen the defensive side of your portfolio by checking companies in the solid balance sheet and fundamentals stocks screener (385 results). Spot lesser known businesses before they hit the mainstream by reviewing the screener containing 589 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Hansoh Pharmaceutical Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2624618973","isCrawlerRequest":true}